Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The treatment with SA still leaves some questions unanswered. Firstly, SA treatment often
results in a concomitant suppression of the insulin secretion, which might lead to clinically
significant glucose intolerance. Secondly, the traditional evaluation of disease activity by
measuring circulating levels of GH and total IGF-I is not reliable enough
Hypotheses: Treatment of acromegaly with SA versus surgery alone is associated with:
- Glucose intolerance despite normalized insulin sensitivity
- Modified peripheral GH activity in peripheral target organs assessed on molecular
endpoints